Evidence map›Paper›PMID 28482922›Full record

ArticleParasites & vectors2017

Therapeutic effect of Schistosoma japonicum cystatin on bacterial sepsis in mice.

Huihui Li, Shushu Wang, Bin Zhan, Wenxin He, Liang Chu, Dapeng Qiu, Nan Li, Yongkun Wan, Hui Zhang, Xingzhi Chen and 3 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  3. Frontiers in cellular and infection microbiology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Micromotor-Enabled Active Hydrogen and Tobramycin Delivery for Synergistic Sepsis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  9. Type I Cystatin Derived fromPathogens (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. DoesCells · 2021
    Review
  16. Molecular medicine reports · 2021
    Article
  17. Article
  18. Review
  19. Therapeutic Efficacy of Excretory-Secretory Products ofFrontiers in cellular and infection microbiology · 2021
    Article
  20. Therapeutic Effect ofFrontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Huihui LiBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Shushu WangPediatrics Department of Affiliated Provincial Hospital of Anhui Medical University, Hefei, 230001, China.
Bin ZhanSection of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Wenxin HeBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Liang ChuSecond Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Dapeng QiuSecond Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
Nan LiBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Yongkun WanBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Hui ZhangBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Xingzhi ChenBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Qiang FangBasic Medical College of Bengbu Medical College, Bengbu, 233000, China.
Jilong ShenDepartment of Immunology, Anhui Medical University, Hefei, 230022, China.
Xiaodi YangBasic Medical College of Bengbu Medical College, Bengbu, 233000, China. yxd_qf@163.com.
Bengbu Medical College · CNAnhui Medical University · CNThe Second Affiliated Hospital of Bengbu Medical College · CNBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSepsis is a life-threatening complication of an infection and remains one of the leading causes of mortality in surgical patients. Bacteremia induces excessive inflammatory responses that result in multiple organ damage. Chronic helminth infection and helminth-derived materials have been found to immunomodulate host immune system to reduce inflammation against some allergic or inflammatory diseases. Schistosoma japonicum cystatin (Sj-Cys) is a cysteine protease inhibitor that induces regulatory T-cells and a potential immunomodulatory. The effect of Sj-Cys on reducing sepsis inflammation and mortality was investigated.

methodsSepsis was induced in BALB/c mice using cecal ligation and puncture (CLP), followed by intraperitoneal injection of different doses (10, 25 or 50 μg) of recombinant Sj-Cys (rSj-Cys). The therapeutic effect of rSj-Cys on sepsis was evaluated by observing the survival rates of mice for 96 h after CLP and the pathological injury of liver, kidney and lung by measuring the levels of alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and creatinine (Cr) in sera and the tissue sections pathology, and the expression of MyD88 in liver, kidney and lung tissues. The immunological mechanism was investigated by examining pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and IL-10 and TGF-β1 in mice sera and in culture of macrophages stimulated by lipopolysaccharides (LPS).

resultsrSj-Cys treatment provided significant therapeutic effects on CLP-induced sepsis in mice demonstrated with increased survival rates, alleviated overall disease severity and tissue injury of liver, kidney and lung. The rSj-Cys conferred therapeutic efficacy was associated with upregualted IL-10 and TGF-β1 cytokines and reduced pro-inflammatory cytokines TNF-α, IL-6, IL-1β. MyD88 expression in liver, kidney and lung tissues of rSj-Cys-treated mice was reduced. In vitro assay with macrophages also showed that rSj-Cys inhibited the release of pro-inflammatory cytokines and mediator nitric oxide (NO) after being stimulated by lipopolysaccharide (LPS).

conclusionsThe results suggest the anti-inflammatory potential of rSj-Cys as a promising therapeutic agent on sepsis. The immunological mechanism underlying its therapeutic effect may involve the downregulation of pro-inflammatory cytokines and upregulation of IL-10 and TGF-β1 cytokines possibly via downregulation of the TLR adaptor-transducer MyD88 pathway. The findings suggest rSj-Cys is a potential therapeutic agent for sepsis and other inflammatory diseases.

Indexed as

AnimalsCecumCystatinsCysteine Proteinase InhibitorsCytokinesImmunomodulationInflammationInterleukin-10Interleukin-6LipopolysaccharidesMacrophagesMiceMice, Inbred BALB CNitric OxideRecombinant ProteinsSchistosoma japonicumCystatinsCysteine Proteinase InhibitorsCytokinesInterleukin-10Interleukin-6LipopolysaccharidesNitric OxideRecombinant ProteinsTransforming Growth Factor beta1Tumor Necrosis Factor-alphaCecal ligation and punctureCystatinImmunomodulationSchistosoma japonicumSepsis

Identifiers

PMID28482922
PMCPMC5422996
OpenAlexW2612867798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.